Table 3.

Logistic regression (univariate and multivariate) assessing the impact of main characteristics on the risk of recurrence (reference: nonrecurrent patients).

Characteristics		Recurrent patients	Nonrecurrent patients	Univariate OR [CI 95%]	P value	Multivariate OR [CI 95%] §	P value
Total		54	57
Age	<60 years 60-69 years ≥70 years	14 (25.9%) 19 (35.2%) 21 (38.9%)	9 (15.8%) 26 (45.6%) 22 (38.6%)	1 0.47 [0.17-1.31] 0.61 [0.22-1.72]	0.15
Sex*	Female Male	21 (38.9%) 33 (61.1%)	21 (36.8%) 36 (63.2%)	1 0.92 [0.43-1.97]	0.82
Tumor location*	Right-sided Left-sided Rectal	20 (37.0%) 21 (38.9%) 13 (24.1%)	23 (40.4%) 22 (38.6%) 12 (21%)	1 1.10 [0.47-2.56] 1.24 [0.47-3.34]	0.66
Lymph nodes analyzed	<12 >12	11(20.4%) 43 (79.6%)	11 (19.3%) 46 (80.7%)	1 0.93 [0.37-2.38]	0.89
T stage	T2-3 T4	39 (72.2%) 15 (27.8%)	50 (87.7%) 7 (12.3%)	1 2.75 [1.02-7.39]	0.045	1 2.58 [0.91-7.32]	0.07
VELIPI criteria†	None or unknown One or more	34 (70.0%) 20 (30.0%)	40 (70.2%) 17 (29.8%)	1 1.12 [0.63-3.06]	0.42
Emergency surgery	No Yes	37 (68.5%) 17 (31.5%)	47 (82.5%) 10 (17.5%)	1 2.16 [0.89-5.27]	0.09	1 1.61 [0.62-4.24]	0.33
Differentiation	Well or moderate Poor or Unknown	49 (90.7%) 5 (9.3%)	50 (87.7%) 7 (12.3%)	1 0.73 [0.22-2.45]	0.61
Neoadjuvant CRT*	No Yes	44 (81.5%) 10 (18.5%)	52 (91.2%) 5 (8.8%)	1 2.36 [0.75-7.44]	0.14
Adjuvant CT*	No Yes	32 (59.3%) 22 (40.7%)	33 (57.9%) 24 (42.1%)	1 0.95 [0.44-2.01]	0.88
Postoperative ctDNA status	Negative Positive	45 (83.3%) 9 (16.7%)	56 (98.2%) 1 (1.8%)	1 11.20 [1.37-91.71]	0.02	1 11.13 [1.33-92.91]	0.03

*Nonrecurrent patients were initially matched with recurrent patients on these factors. ^§ Multivariate regression model includes variables with a p value less than 0.1 in univariate analysis ^†VELIPI criteria include vascular, lymphatic and/or perineural invasion. CRT, chemoradiotherapy; CT, chemotherapy; ctDNA, circulating tumor DNA.

Bold values correspond to p values lower than 0.05.